News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sepragen (SPGNA) Announces the Completion of Cyto Biologic Technologies Acquisition


12/6/2007 10:15:28 AM

HAYWARD, Calif.--(BUSINESS WIRE)--Sepragen Corporation (Pink Sheets:SPGNA), a provider of patented technology and equipment for bio-processing needs in the biotech industry, today announced that it has completed the acquisition of Cyto Biologic Technologies, Inc. Terms of the acquisition were not disclosed. Of the acquisition, Vinit Saxena, CEO of Sepragen, stated, “The consummation of the acquisition of Cyto Biologic Technologies allows Sepragen to provide our bio-processing customers with an innovative technology to rapidly grow cells to high densities with resultant higher productivity.” Saxena continued, “What is most significant is that this is the first step in transforming Sepragen from being a supplier of individual tools to becoming a value-added solution provider in the bio-processing space. Cells grown on the bioreactor produce biological molecules, which can be further processed by several technologies, including Sepragen columns, resins and QuantaSep systems.”

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES